| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e312f29289f816dfa25f551501aa1c95 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-15 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-2013
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-33
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-3955
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-57 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-15
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-33 |
| filingDate |
2020-04-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_23ba424d13c62d3c8d937f602d137285
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0c256e482980b143f6c6335bfd754cd3 |
| publicationDate |
2022-03-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-3962504-A1 |
| titleOfInvention |
Enhancement of fibroblast therapeutic activity by t cell modulation |
| abstract |
Embodiments of the disclosure concern methods and compositions for enhancing therapeutic efficacy of fibroblast therapy for an individual in need thereof. The disclosure concerns administering to the individual one or both of interleukin-2 (IL-2) and one or more anti-CD3 agents to enhance efficacy of the fibroblast therapies. In specific cases, the IL-2 is provided to the individual at particular low doses, and the anti-CD3 agent may be a monoclonal antibody. |
| priorityDate |
2019-04-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |